400 Pleasant Street
United States - Map
pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable sustained-release micro-insert delivering fluocinolone acetonide for the treatment of vision impairment associated with chronic diabetic macular edema; and Retisert for the treatment of posterior uveitis. The companys ILUVIEN is also studied in two Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It also develops Medidur, which is in Phase III clinical trials for the treatment of posterior uveitis; TBD that is in Phase I/II clinical trial for the treatment of glaucoma; and glaucoma latanoprost product candidate, which is an injectable bioerodible drug delivery micro-insert for the treatment of glaucoma and ocular hypertension. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Intrinsiq Materials Cayman Limited; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
|Dr. Paul Ashton B.Sc., Ph.D.,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Leonard S. Ross ,
Principal Financial & Accounting Officer and VP of Fin.
|Ms. Lori H. Freedman Esq., B.A., J.D.,
VP of Corp. Affairs, Gen. Counsel and Company Sec.
|Mr. Marty Nazzaro ,
VP of Operations
|Mr. Brian Leedman B.Econ., M.B.A.,
VP of Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|